Catalent Biologics Announces Appointment Of Dr. Graham Brearley As General Manager Of Its Madison, Wisconsin Facility
SOMERSET, N.J. – June 26, 2018 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Graham Brearley, Ph.D., has been appointed as General Manager of the company’s Madison, Wisconsin facility. He will report to Brian Riley, Vice President of Operations, Biologics & Specialty Drug Delivery.
In his most recent position, Dr. Brearley served as Senior Director, Technical Operations with Shire, where he was responsible for leading strategy, organization, execution and business processes. With a proven track record in providing technical expertise on operational aspects of the bioscience business, including process development and life cycle management, he has over 25 years’ technical, operations and business experience in the biopharmaceutical industry.
Prior to that, Dr. Brearley held leadership positions at organizations including Sigma-Aldrich and Baxter. He has a bachelor’s degree in applied biology from Thames Polytechnic, U.K. and a doctorate in biochemistry from the Council of National Academic Awards.
Opened in April 2013 and recently expanded, Catalent Biologics’ Madison facility provides development, manufacturing and analytical services for new biological entities and biosimilars, and is the home of the company’s proprietary GPEx® cell line technology, used to create high-yielding mammalian cell lines. The Madison facility was designed for flexible cGMP production, from 10 to 4,000-liter scale, and non-GMP production up to 250-liter scale, and features extensive use of single-use technologies and unidirectional flow to maximize efficiency. Manufacturing is supported by integrated analytical, process and formulation development capabilities and separate microbiology and quality control functions.
For further information visit biologics.catalent.com
+44 (0)7580 041073
+44 (0) 161 728 5880
Catalent, Inc. (NYSE: CTLT), is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 10,000 people, including over 1,400 scientists, at more than 30 facilities across five continents, and in fiscal 2017 generated over $2 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.catalent.com.